Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Other Accumulated Expenses (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Other Accumulated Expenses for 6 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses changed N/A year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Sep 2025, changed N/A, and an annual FY2024 reading of $2.1 million, down 48.24% over the prior year.
  • Other Accumulated Expenses was $2.5 million for Q3 2025 at Treace Medical Concepts, down from $3.2 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $4.5 million in Q1 2024 and bottomed at $1.1 million in Q4 2021.
  • Average Other Accumulated Expenses over 5 years is $2.8 million, with a median of $2.5 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses skyrocketed 144.9% in 2021, then plummeted 48.24% in 2024.
  • Year by year, Other Accumulated Expenses stood at $1.1 million in 2021, then skyrocketed by 64.63% to $1.8 million in 2022, then surged by 123.4% to $4.0 million in 2023, then plummeted by 48.24% to $2.1 million in 2024, then rose by 22.57% to $2.5 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for TMCI at $2.5 million in Q3 2025, $3.2 million in Q1 2025, and $2.1 million in Q4 2024.